Navigation Links
Mayo Clinic researchers discover new form of cancer
Date:6/10/2014

ROCHESTER, Minn. June 10, 2014 This is the story of two perfectly harmless genes. By themselves, PAX3 and MAML3 don't cause any problems. However, when they combine during an abnormal but recurring chromosomal mismatch, they can be dangerous. The result is a chimera a gene that is half of each and that causes biphenotypic sinonasal sarcoma. The tumor usually begins in the nose and may infiltrate the rest of the face, requiring disfiguring surgery to save the individual. Because Mayo Clinic pathology researchers have now described the molecular makeup of the rare tumor, several existing cancer drugs may be targeted against it. The findings appear in the current issue of Nature Genetics.

In 2004, Mayo Clinic pathologists Andre Oliveira, M.D., Ph.D., and Jean Lewis, M.D., first noticed something unusual about a tumor sample they were analyzing under the microscope. By 2009, they had seen the same pathology several times and had begun collecting data. In 2012, they and a team of Mayo collaborators published their discovery and defined a new class of tumor not previously described. Now, less than two years later, they are informing the medical community of the "nature of the beast" the genetic structure and molecular signature of this seldom-recognized type of cancer, which seems to strike women 75 percent of the time. It is rare, but how rare no one knows as most of the cases they examined were initially diagnosed as various other types of cancer. They were able to first identify and then characterize it because Mayo Clinic is considered one of the world's largest referral centers for sarcoma diagnosis and treatment.

"It's unusual that a condition or disease is recognized, subsequently studied in numerous patients, and then genetically characterized all at one place," says Dr. Oliveira, who subspecializes in the molecular genetics of sarcomas. "Usually these things happen over a longer period of time and involve separate investigators and institutions. Because of Mayo's network of experts, patient referrals, electronic records, bio repositories, and research scientists, it all happened here. And this is only the tip of the iceberg. Who knows what is in our repositories waiting to be discovered."

First Seen Nearly 60 Years Earlier

While the cancer wasn't formally identified until 2009, a subsequent search of Mayo Clinic's medical records showed that a Mayo patient had the cancer in 1956. The identical description was found in physician notes within Mayo's computerized database and confirmed with careful microscopic analysis. Dr. Oliveira took his investigation one step further and located that patient's original tumor samples kept all those years in Mayo's bio repositories. His analysis confirmed that the tumor possessed this same genetic chimera. In a way, Mayo Clinic had discovered the same rare cancer twice. The notes from the original physician added to the findings of the more recent discovery. For Dr. Oliveira, it was a surprising but not unheard of "collaboration" with a Mayo colleague from two generations ago.

Significance of the Discovery

Other than the increased knowledge about this rare cancer, its mechanisms and the potential for a treatment drug, researchers also are interested in the discovery because of its potential as a disease model.

"The PAX3-MAML3 chimera we identified in this cancer has some similarities to a unique protein found in alveolar rhabdomyosarcoma, a common cancer found in children," says Mayo Clinic molecular biologist and co-author Jennifer Westendorf, Ph.D. "Our findings may also lead to a better understanding of this pediatric disease for which, unfortunately, there is no specific treatment."


'/>"/>

Contact: Robert Nellis
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. First clinical diabetes registry to provide seamless view of patients across specialties
2. Clinical review published in JAMA
3. Five-question clinical tool the first to help screen risk of violence in military veterans
4. Mayo Clinic moves small-molecule drugs through blood-brain barrier
5. New definition of kidney disease for clinical trials could lead to new treatments
6. American Society of Clinical Oncology recognizes MD Anderson leaders for their contributions to cancer research
7. Myriad presents clinical data on Myriad myRisk Hereditary Cancer Test at ASCO
8. Mayo Clinic: Ovarian cancer subtypes may predict response to bevacizumab
9. Mount Sinai researchers to present studies at American Society of Clinical Oncology Meeting
10. Moffitt Cancer Center instrumental in new clinical guidelines for cancer-related fatigue
11. UH part of $7.5M NIH clinical trial on nearsightedness in children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... Smithtown, New York (PRWEB) , ... January 16, ... ... group, SightMD today announced the addition of Victor Giamos, MD to ... Officer of SightMD and Managing Partner at North Shore Eye Care, a division ...
(Date:1/16/2017)... ... ... are well-aware of the following facts at present:, Flu and ... no effect on keeping this particularly bad strain of the flu away , ... sniffling , These facts are well-known among the team at Woodard! About ...
(Date:1/16/2017)... CITY, UT (PRWEB) , ... January 16, 2017 , ... ... disease not only to treat, but to test for, as well. The money spent ... billion every year.(1) Doctors in the U.S. screen patients for cancer more than in ...
(Date:1/15/2017)... ... , ... In this role, Courtney will be responsible for developing new business ... friendly mark. This certification program was created by ASL and the nonprofit Asthma and ... suitable for the 60+ million people living in the U.S. with asthma and allergies. ...
(Date:1/15/2017)... ... 15, 2017 , ... "On Tour is a music themed slideshow production package ... Christina Austin - CEO of Pixel Film Studios. , On Tour’s new slide ... and animation of their slideshows. Place each slide on top of another slide or ...
Breaking Medicine News(10 mins):
(Date:1/13/2017)... , January 13, 2017 This ... see how they have fared at yesterday,s closing bell: ... Biopharma Inc. (NASDAQ: GALE ), and ACADIA ... harness cellular and biomolecular processes to develop technologies and ... environmental footprint, feed the hungry, use less and cleaner ...
(Date:1/13/2017)... 2017 The 2016 election resulted in ... states voting in favor of legalizing cannabis for recreational use, ... in the U.S. In addition, the state of ... cannabis products sales. The ArcView Group has published an updated ... cannabis sales in the U.S. last year reached $6.7 billion, a ...
(Date:1/13/2017)... 2017   JDRF , the leading global ... pleased to announce that after more than a ... & Medicaid Services (CMS) has recognized continuous glucose ... use in making diabetes treatment decisions as durable ... eligible for coverage under Medicare. JDRF has been ...
Breaking Medicine Technology: